CDK2 and hepatocellular carcinoma: qRT-PCR analysis of the uninfected hepatoma cells revealed a reduction in CDK1, CDK2, CCNB1, CCND1, and CCND2 expression upon treatment with sorafenib or lenvatinib, suggesting that these drugs can effectively disrupt cell cycle progression, corroborating previous reports on the mechanisms of TKIs in inhibiting cell proliferation [4,6].